SCHEMBL521899

SCHEMBL521899

NC(=O)CN1CCN(c2ccc(N)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
ALDH1A1 P00352 5/20 0.55
GFER P55789 3/20 0.55
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
THRB P10828 1/20 0.49
ALOX15 P16050 1/20 0.49
YWHAG P61981 1/20 0.49
HTT P42858 1/20 0.48
SLC6A9 P48067 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
GAA P10253 3/20 0.44
NSD2 O96028 1/20 0.44
ALPL P05186 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27908174 0.89 MAPT (0.58) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL13419681 0.87 MAPT (0.54) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL28195441 0.84 MAPT (0.56) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL10036404 0.82 L3MBTL1 (0.51) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL17265648 0.81 ALDH1A1 (0.77) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL27597072 0.81 ALDH1A1 (0.64) MAPTALDH1A1GFERLMNATDP1
SCHEMBL521490 0.80 MAPT (0.61) MAPTALDH1A1LMNAMAPK1MEN1
SCHEMBL3435091 0.80 ALDH1A1 (0.57) MAPTALDH1A1HSD17B10KDM4EMEN1
SCHEMBL3027517 0.79 MAPT (0.57) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL159281 0.79 MAPT (0.68) MAPTALDH1A1GFERLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 MAPT 3109/4885ALDH1A1 779/4885GFER 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.